A5050291961- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- Advanced Breast Cancer Therapies
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Breast Cancer Treatment Studies
- Immunotherapy and Immune Responses
- Neuroendocrine Tumor Research Advances
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Liver physiology and pathology
- Cancer, Lipids, and Metabolism
Hospital del Mar Research Institute
2013-2024
Hospital Del Mar
2015-2024
Institut de recherche mathématique de Rennes
2023
Municipal Institute for Medical Research
2013-2022
Centro de Investigación Biomédica en Red de Cáncer
2019
Universitat Pompeu Fabra
2013
Research Network (United States)
2013
Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects hepatocyte growth factor (HGF)/Met-mediated epithelial-to-mesenchymal transition (EMT) SCLC and evaluate role inhibition mesenchymal/chemorefractory models.SCLC models HGF-induced EMT were evaluated vitro vivo (subcutaneous xenografts BALB/c nude mice) for chemosensitivity response PF-2341066 (crizotinib). Human samples at diagnosis (N =...
The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation platforms is rapidly becoming accepted as a tool for measuring both research use. Fresh frozen (FF) tissue specimens GBM are difficult obtain since tumor obtained at surgery often scarce necrotic diagnosis prioritized over freezing. After diagnosis, leftover usually stored formalin-fixed...
// Raúl Rincón 1, * , Ion Cristóbal Sandra Zazo 2 Oriol Arpí 4 Silvia Menéndez Rebeca Manso Ana Lluch 3 Pilar Eroles Rovira Joan Albanell Jesús García-Foncillas 1 Juan Madoz-Gúrpide Federico Rojo 2, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital "Fundación Jiménez Diaz", Madrid, Spain Pathology Department, IIS of INCLIVA, Valencia, Medical del Mar, Barcelona, These authors have contributed equally to this work Correspondence to:...
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts personalized clinical management and the development of innovative strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict efficacy HER2-targeted independently from clinicopathological factors primary HER2-positive breast cancer patients. Understanding mechanism/s underlying this association would contribute optimizing patient stratification provide rationale for...
Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated pulse-fashion with induce resistant phenotype. Cellular molecular effects parental versus compared. CDK1 kinase activity cyclin B1 expression assayed under various conditions. Genetic modifications up- or...
Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines two cohorts SCLC before during treatment with chemotherapy or without ipilimumab correlate them survival.Patients methods. Two were studied: treated (n = 47), plus 37). Baseline, on-treatment after-treatment samples evaluated for the presence IL-1beta, IL-2, IL-4,...
Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, ultimately develop disease progression, often driven by acquisition of mutations the extracellular domain (ECD) EGFR. Sym004 is a novel 1:1 mixture two nonoverlapping mAbs that recently showed promising activity phase I trial MCRC. Our aim was to determine efficacy circumvent resistance EGFR ECD mutations.Functional studies were performed...
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms acquired resistance trastuzumab in by using well-established cell line-based preclinical models, as well samples from patients with HER2-positive treated trastuzumab. studied NCI-N87 and OE19, two lines that overexpress HER2 receptor are sensitive. Differences at protein, DNA, RNA levels between parental resistant cells were...
Small cell lung carcinoma (SCLC) has poor prognosis and remains orphan from targeted therapy. MET is activated in several tumour types may be a promising therapeutic target. To evaluate the role of SCLC, gene status protein expression were evaluated panel SCLC lines. The inhibitor PHA-665752 was used to study effects pathway inhibition basal hepatocyte growth factor (HGF)-stimulated conditions. Immunohistochemistry for p-MET performed human samples association with outcome assessed. In...
HER2-positive breast cancer is currently managed with chemotherapy in combination specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due molecular alterations the tumor that are unknown undetermined clinical practice. Those may cause be refractory treatment trastuzumab, promoting proliferation and metastasis. Using continued exposure cell line we...
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction patients respond to treatment. To better understand which factors drive clinical benefit, we generated whole exome RNA sequencing data from 27 urothelial carcinoma treated with anti-PD-(L)1 monoclonal antibodies. We assessed influence on response non-synonymous mutations (tumor mutational burden or TMB), clonal...
// Alba Dalmases 1,2 , Irene González Silvia Menendez Oriol Arpí Josep Maria Corominas 3 Sonia Servitja Ignasi Tusquets 1,2,4 Cristina Chamizo 5 Raúl Rincón Lluis Espinosa 1 Anna Bigas Pilar Eroles 6 Jessica Furriol Lluch 7,8 Ana Rovira Joan Albanell 1,2,9 Federico Rojo 1,5 Cancer Research Program, IMIM (Hospital del Mar Institute), Barcelona, Spain; 2 Medical Oncology Department, Hospital Mar, Pathology 4 Autonomous University of IIS-Fundación Jiménez Díaz, Madrid, Institute Health INCLIVA,...
// Israel Cañadas 1,* , Álvaro Taus 2,* Iria González 2 Xavier Villanueva Javier Gimeno 3 Lara Pijuan Manuel Dómine 4 Albert Sánchez-Font 5 Ivan Vollmer 6 Silvia Menéndez 1 Oriol Arpí Sergi Mojal 7 Federico Rojo 8 Ana Rovira 1,2 Joan Albanell 1,2,9 and Edurne Arriola 1. Cancer Research Program, IMIM (Hospital del Mar Medical Institute), Doctor Aiguader, Barcelona 2. Servei d'Oncologia Médica, Hospital Mar, Passeig Marítim, 3. de Patologia, 4. Oncology Department, IIS-Fundación Jiménez Díaz,...
Natural killer (NK) cells can orchestrate effective antitumor immunity. The presence of tumor-infiltrating NK in diagnostic biopsies predicts pathologic complete response (pCR) to HER2-specific therapeutic antibodies patients with primary breast cancer. Here, we analyzed whether diversity circulating might influence tumor infiltration and antibody efficacy. We found that numbers CD57+ inversely correlated pCR treatment cancer independently age, traditional clinicopathologic factors, CD16A...
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers treatment outcome, we assessed NAAs in serial samples from SCLC patients treated chemoimmunotherapy compared to chemotherapy alone. We evaluated 2 cohorts: cohort 1 (C1), 47 received standard platinum/etoposide, and (C2), 38 ipilimumab, carboplatin etoposide. Serum at baseline subsequent time points were analyzed for presence NAAs. detected...
Advanced bladder cancer is associated with a poor prognosis and limited treatment options. The PI3K/AKT/mTOR pathway frequently activated in this disease can be potential therapeutic target for intervention. We studied the antitumor efficacy of new targeted therapy, TAK-228 (oral mTORC1/2 inhibitor), preclinical models cancer. evaluated effects combination PI3Kα inhibitor (TAK-117) or chemotherapy (paclitaxel). used six cell lines vivo xenografts models. strongly inhibited proliferation...
Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed identify, quantify, and assess mechanisms of trastuzumab. established an trastuzumab-resistant model in vitro from BT-474, a trastuzumab-sensitive, HER2-amplified breast-cancer cell line. A multi-omic strategy was implemented obtain gene, proteome, phosphoproteome signatures associated with trastuzumab followed...
Abstract Purpose: Molecular subtype classifications in glioblastoma may detect therapy sensitivities. IHC would potentially allow the identification of molecular subtypes routine clinical practice. Experimental Design: Formalin-fixed, paraffin-embedded tumor samples 124 uniformly treated, newly diagnosed patients with were submitted to RNA sequencing, IHC, and immune-phenotyping identify differences associated treatment Results: We detected high overlapping The Cancer Genome Atlas (TCGA)...
The development and progression of true interval breast cancers (tumors that truly appear after a negative screening mammogram) is known to be different from screen-detected cancers. However, the worse clinical behavior not fully understood biologic basis. We described differential patterns gene expression through microarray analysis in cancers.An unsupervised exploratory profile was performed on 10 samples (true = 5; 5) using Affymetrix Human Gene 1.0ST arrays interpreted by Ingenuity...
Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification identification new targets. Cancer Genome Atlas (TCGA) mainly been applied U.S. clinical trials, while intrinsic glioma (IGS) European trials.From paraffin-embedded samples 432 patients with uniformly treated, newly diagnosed glioblastoma, we built tissue microarrays for IHC analysis RNA sequencing best...
2029 Background: Glioblastoma (GBM) gene expression subtypes have been described in last years, data homogeneously treated patients is lacking. Methods: Clinical, molecular and immunohistochemistry (IHC) analysis from with newly diagnosed GBM standard radiochemotherapy were studied. Samples classified based on the profiles into three different (classical, mesenchymal, proneural) using Support Vector Machine (SVM), K-nearest neighbor (K-NN) single sample Gene Set Enrichment Analysis (ssGSEA)...
<div>Abstract<p><b>Purpose:</b> Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.</p><p><b>Experimental Design:</b> cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated pulse-fashion with induce resistant phenotype. Cellular molecular effects parental versus compared. CDK1 kinase activity...